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Abstract
Background: Maternal-fetal genotype incompatibility (MFGI) is increasingly reported to influence human diseases,
especially pregnancy-related complications. In practice, it is challenging to identify the ideal incompatibility model for
analysis, since the true MFGI mechanism is generally unknown. The underlying MFGI mechanism for different genetic
variants can vary, and to use a single incompatibility model for all circumstances would cause power loss in testing
MFGI.
Results: In this article, we propose a practical 2-step procedure that incorporates a model selection strategy based
on an entropy measurement to select the most appropriate MFGI model represented by data and test the
significance of the MFGI effect using the chosen model within the generalized linear regression framework.
Conclusions: Our simulation studies show that the proposed two-step procedure controls the type I error rate and
increase the testing power under various scenarios. In a real data application, our analysis reveals genes having an
MFGI effect, which may not be detected with a non-model selection counterpart.
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Background
Current advances in high-throughput biotechnology have
popularized genome-wide association studies (GWAS) to
detect genetic variants that increase the risk of com-
plex diseases. Over the past decade, thousands of single
nucleotide polymorphisms (SNPs) have been reported to
be associated with various human diseases. Despite the
numerous successes of GWAS, the majority of heritabil-
ity for many complex diseases remains unexplained [1-5].
Recent genomic research provides compelling evidence
that the cause of complex human diseases is multifactorial
and involves both genetic and environmental factors. The
lack of consideration of sophisticated components like
gene-gene interactions, gene-environment interactions,
and epigenetic functions can lead to the missing heritabil-
ity for most common diseases.
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The underlying genetic architecture can be espe-
cially complicated for diseases developed during human
pregnancy, since both maternal and fetal genomes are
involved. In general, the fetus inherits one copy of the
genome from each of its parents, and the two copies are
not identical. Previous family-based or twin studies indi-
cated that the heritability for obstetric diseases is high.
For example, it is reported in an earlier twins study that
heritability was 17% for preterm delivery in first preg-
nancy and 27% for preterm delivery in any pregnancy
[6] and heritability range of 25%–40% was suggested
for birthweight and gestational length in another study
[7]. Maternal and fetal genes, either individually or in
combination, could increase the risk of diseases such as
hemolytic disease of the newborn [8], pretermbirth [9,10],
small for gestational age [11], pre-eclampsia [12-14], and
preterm prelabor rupture of membranes (pPROM) [15].
The incompatibility between maternal and fetal geno-
types, in which the expression of genes from two gen-
erations lead to an opposite effect, plays a vital role and
can increase the risk of these diseases. However, most
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current association studies on obstetric diseases have pri-
marily focused on only one genome for susceptibility
genomic loci; that is only thematernal or fetal genome was
searched for associated genetic factors when amaternal or
fetal disorder was studied.
Evidence support the important role of interaction
between maternal and fetal genes, more than maternal
genes alone for the etiology of pregnancy complications,
are accumulating [16-19]. In other words, an increased
risk of certain disorders could be due to a specific combi-
nation of maternal and fetal genotypes. The mother and
fetus share only one allele. Mismatches between mater-
nal and fetal genotypes may lead to adverse effects when
a fetus resides in utero and increase the risk of disease.
A good example of this deleterious effect comes from
the allogenic response. If a bi-allelic locus has a null
allele and an antigen-coding allele, the mother is homozy-
gous for the null allele, and the fetus inherits an allele
from the father which codes for an antigen, the mother
may produce an allogenic response to the fetal antigen,
which is harmful to the fetus. This type of incompatibility
betweenmaternal and fetal genotypes is well illustrated by
Rh incompatibility, which is developed when a pregnant
woman is Rh-negative (d/d) and the fetus is Rh-positive
(D/d) in the RhD locus. Red blood cells from the fetus
can cross into the maternal blood stream through the pla-
centa. The maternal immune system treats Rh-positive
fetal cells as external attacks and makes antibodies against
the fetal blood cells. These antibodies may cross back
into the developing fetus and destroy its circulating
blood cells, which can cause hemolytic disease of the
newborn (HDN). Therefore, the identification of genes
with maternal-fetal genotype incompatibility (MFGI) by
searching parental and offspring genomes simultaneously
is highly recommended [20-26].
Study designs in which data are collected from parent-
offspring triads or mother-offspring dyads are the most
commonly used to investigate the marginal and joint
effects of maternal and fetal genes. Most currently avail-
able statistical approaches for analyzing this type of data
fall in the framework of generalized linear regression
models. Maternal fetal genotype tests based on the log-
linear modeling for child-parent triads have been devel-
oped [20,27-29]. These tests are robust to population
stratification because they compare the distribution of
affected and unaffected individuals given the parental
mating type instead of comparing frequencies of alle-
les/genotypes between cases and controls. However, these
tests and their extensions require at least some paternal
data are available. For situations when paternal data are
100% missing, the dyad sampling data, methods based on
logistic regression models were proposed [22,23,25].
Although it has been widely hypothesized that mis-
matches between maternal and fetal genotypes can cause
incompatibility, the underlying biological mechanism
remains unclear. Therefore, it is challenging to appro-
priately model incompatibility and code the correspond-
ing variable accordingly. That is, suppose a variable Gic
denotes the MFGI effect, it is problematic to decide when
to code the variable as 1 or 0. Parimi et al. [30] evaluated
the performance of 6 plausible incompatibility models and
concluded that the most comprehensive model, which
codes genotype incompatibility whenever maternal and
fetal genotypes are different, consistently outperformed
othermodels. However, only thematernal-fetal incompat-
ibility effect was simulated in their study, and thematernal
main effect and the fetal main effect were not considered
along with MFGI. When a maternal or fetal main effect
co-exists with MFGI, this approach dramatically inflates
the type I error. Even if only an incompatibility effect is
present, the recommended model does not always achieve
greater power than the true incompatibility models.
In this study, we developed a 2-step statistical strat-
egy for testing MFGI effects in designs that collect data
from the mother and offspring that can increase the test-
ing power under a wide range of scenarios. We propose
to select the MFGI model based on an entropy measure-
ment via a permutation procedure; then we test the MFGI




Consider a study that enrolls case and control mother-
offspring pairs from a target population. Collected data
include genotypes of mothers and offspring, disease phe-
notype (phenotype of mother or child) of interest, and
other covariates with a total of n independent mother-
offspring pairs (n0 controls and n1 cases, n1 + n0 = n).
Let Gm and Go denote the maternal and fetal genotypes
of a particular SNP, respectively. Under the commonly
used additive genetic model, Gm/o = 0, 1, or 2 if the
mother/offspring has 0, 1, or 2 copies of the minor allele.
Let Y = (y1, y2, · · · , yn)T denote the vector of the phe-
notype, where yi is the dichotomous disease outcome of
the ith family unit in the sample, in which yi = 1 or 0
corresponds to the affected or unaffected individuals.
Consider a bi-allelic genomic locus with 2 alleles:
A and a, where A denotes the rare allele. Follow-
ing the Mendelian inheritance, there are seven possi-
ble maternal-fetal genotype combinations (see Table 1).
The 4 mismatched maternal-fetal genotype combinations
are denoted as M1,M2,M3, and M4. It is possible that
any of the mismatched maternal-fetal genotype combi-
nation leads to incompatibility or that only a specific
mismatched genotype combination or a certain collec-
tion of these genotype combinations is associated with
the risk of disease. Therefore, in the absence of evidence
Li et al. BMC Genetics 2014, 15:66 Page 3 of 10
http://www.biomedcentral.com/1471-2156/15/66
Table 1 Possiblematernal-fetal genotype combinations
Go
Gm AA(2) Aa(1) aa(0)
AA(2) 0 M1 -
Aa(1) M2 0 M3
aa(0) - M4 0
from molecular genetics analysis, it is challenging to
determine which incompatibility model fits the biological
mechanism. Here, we consider 11 biologically-plausible
incompatibility models (Table 2) and propose a 2-step
procedure to identify genomic loci that have a MFGI
effect on a disease outcome of interest. We first select an
MFGI model based on an entropy measurement and then
Table 2 Biologically plausiblemodels of maternal-fetal
genotype incompatibility
Model GC Gm Go Scenario
1 M1 AA Aa Mother has 1more copy of allele A than
the heterozygous offspring
2 M2 Aa AA Offspring has 1 more copy of allele A
than the heterozygous mother
3 M3 Aa aa Mother has risk allele A that the
offspring does not
4 M4 aa Aa Offspring has risk allele A that the
mother does not
5 M1 AA Aa Mother-offspring pair has 3 copies of A
allele
M2 Aa AA
6 M1 AA Aa Mother has 1 more copy of A allele
M3 Aa aa
7 M1 AA Aa Offspring has an allele that the mother
does not
M4 aa Aa
8 M2 Aa AA Mother has an allele that the offspring
does not
M3 Aa aa
9 M2 Aa AA Offspring has 1 more copy of the A
allele
M4 aa Aa
10 M3 Aa aa Mother-offspring pair possesses 3
copies of allele a
M4 aa Aa







test the statistical significance of MFGI using the chosen
incompatibility model. Details of the 2-step procedure are
described in the following section.
Statistical model
The information theory, which was initially developed in
the 1940s [31] to quantify the transmission of information
in communication channels within a rigorous mathemat-
ical framework, has gained much attention in genetic
association studies in recent years [32-35]. Our aim is to
propose a model selection strategy to choose the MFGI
model best represented by the data using the entropy the-
ory. Before introducing the model selection strategy, we
discuss some basic concepts about the information theory.
Entropy measures the uncertainty of a random variable.




P(X = xi)logbP(X = xi) (1)
where xi, P(X = xi), i = 1, 2, · · · , d are the possible val-
ues of X and their corresponding probabilities; b is the
base of the logarithm and is commonly assumed to be 2 in
the information theory. We propose the following 2-step
procedure to test MFGI effects:
Step 1: Select the MFGI model Let p and 1 − p be pro-
portions of cases and controls, respectively, in a given data
set. Entropy of the disease outcome can be computed
H(D) = −plog2(p) − (1− p)log2(1− p) (2)
This entropy serves as a measure of the uncertainty of
disease outcome in the initial data set.
Under each of the 11 plausible MFGI models listed in
Table 2, the mother or offspring can be characterized as
“high risk” or “low risk” based on their genotype combina-
tions. For example, underModel 1, mother-offspring pairs
with genotype combination M1 = (AA,Aa) are consid-
ered “high risk” and other combinations are considered
“low risk”. The high and low risk labels split the initial
data set into 2 subsets. Entropy of disease outcome within
each subset, H(D|risk = high) and H(D|risk = low), can
be calculated using Equation (2). The conditional entropy
of disease status, given a particular MFGI model, is then
defined as
H(D|MFGI) = H(D|risk = high)P(risk = high)
+H(D|risk = low)P(risk = low) (3)
This conditional entropy measures the remaining
amount of uncertainty of disease outcome given theMFGI
model. The difference between this conditional entropy
and the original entropy is the information gain (ormutual
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information), which reflects the amount of information
that a certain MFGI model provides (Equation (4)).
IG(D;MFGI) = H(D)−H(D|MFGI) (4)
To adjust for the uncertainty of disease status due
to sampling, the information gain ratio was used
(Equation (5)) as the criterion to select the optimal model
to code the MFGI effect.
R = IG(D;MFGI)/H(D) = 1− H(D|MFGI)H(D) (5)
As shown in Table 2, Model 11 is the most com-
prehensive model because it includes all 4 incompati-
ble maternal-fetal genotype combinations. The study by
Parimi et al. (2008) recommends this model as “optimal”
when decoding the MFGI effect. Herein we consider this
model as the default model. The information gain ratio
was calculated for each of the 11 plausible MFGI mod-
els and, then we selected the model that has the largest
information gain ratio as the candidate model. Since a
candidate model could be chosen by chance and does
not reflect the real functional mechanism, a permuta-
tion procedure is used to assess how likely the candidate
model will be chosen under the assumption of no genetic
association as follows:
1. Obtain the information gain ratio
{Ri, i = 1, 2, · · · , 11} for each model and identify the
model with the maximum information gain ratio
Rmax = max{R1,R2, · · · ,R11} as a candidate model;
2. For b = 1, 2, · · · ,B, permute the disease label and
obtain the maximum information gain ratio
Rmaxb = max{R1,b,R2,b, · · · ,R11,b};
3. Calculate the empirical p-value of selecting the
model by chance




If the obtained empirical P-value is less than a pre-
defined cutoff τ (say τ = 0.0001), we can conclude that
the candidate model was not selected by chance and will
be used as the analysis model in the next step of testing.
Otherwise, Model 11 will be used as the analysis model.
Step 2: Test the MFGI effect Once an optimal incom-
patibility model is selected, it will be used to code the
incompatibility effect in a logistic regression model to
assess the significance of the incompatibility effect, that is,
logitP(Y = 1|Gm,Go) = β+βmGm+βoGo+βicGic (6)
where Gm and Go represent the maternal and offspring
additive variables, respectively, which are coded as 0, 1,
or 2 corresponding to aa, Aa, and AA, respectively, where
A is the risk allele; and Gic is the variable of MFGI. The
value of Gic depends on the selection result from Step 1.
For example, if Model 1 is selected as the analysis model,
then Gic = 1 for mother-offspring pairs with genotype
combination (AA,Aa) and Gic = 0 otherwise. Testing the
MFGI effect corresponds to testing the null hypothesis
H0 : βic = 0. The likelihood ratio test was applied for this
purpose.
Simulation
To demonstrate that the proposed approach is valid in
controlling the type I error rate and that it is statisti-
cally powerful, we conducted a series of simulations under
the null and alternative hypotheses. Genotypes of N =
1, 000, 000 families (parents and a child) were generated in
a population assuming symmetric mating and Mendelian
transmission of alleles. Parental genotypes were gener-
ated by multinomial distribution with a pre-specified
genotype frequency. Either the Hardy-Weinberg equilib-
rium (HWE: minor allele frequency=0.2) or the Hardy-
Weinberg disequilibrium (HWD: genotype frequency =
(0.18, 0.47, 0.35) for homozygous carriers, heterozygotes,
and noncarriers of the minor allele, respectively) was
assumed. Fetal genotypes were simulated based on par-
ents’ genotypes following Mendelian inheritance. Pater-
nal data were then dropped to mimic the maternal-fetal
study design. Binary phenotypes were simulated based
on a quantitative liability variable Z = (z1, z2, · · · , zN)T ,
where zi denotes the liability variable of the ith subject. A
threshold was determined to ensure that disease preva-
lence remained at 5%. Mother-offspring pairs with the
underlying quantitative liability that exceeded the thresh-
old were “diagnosed” as affected and others as unaffected.
Simulated data were treated as a population. Then sam-
ples with the size n were randomly taken for subsequent
analysis.
The underlying quantitative liability trait was simulated
through the following regression model (Equation (7)),
z = α + αmGm + αoGo + αicGic + ε (7)
where αs are defined the same way as βs in Equation (6).
Without loss of generality, we set the overall mean α = 0
Table 3 Simulation scenarios with different parameter
values
Scenarios I II III IV V VI VII VIII IX
βm 0 0.4 0 0.4 0 0.2
βo 0 0 0.4 0 0.4 0.2
βic 0 0 0 0.4 0.4 0.4
h2 0.05 0.10 0.15
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and σ 2 = 1. Performance of our proposed two-step
approach (called the model selection approach) was com-
pared with that of its non-model selection counterpart
(called the full model approach). Quantitative data were
generated using a particular MFGI model listed in Table 2,
called the data generating model. Various scenarios were
considered (Table 3): Scenario I assumes no genetic effect
at all; Scenarios II and III generate data under the null
hypothesis of no MFGI effect while allowing maternal
or fetal main effect; Scenarios IV-VI simulate the MFGI
effect along with maternal and/or fetal main effects; and
Scenarios VII-IX assume the MFGI effect only at 3 dif-
ferent heritability levels (h2 = 0.05, 0.10, 0.15). The effect
size of incompatibility was computed as described by
Parimi et al.: let σ 2T = α2icq(1 − q) + σ 2 where q is the
proportion of incompatible maternal-fetal genotypes in
the simulated population. For a given heritability level h2,
we can calculate the incompatibility effect through the
equation h2 = 1− σ 2/σ 2T .
A case study
We illustrated the proposed method via an application
to a sub-analysis of a broader candidate gene study that
investigates the role of genetic factors on the risk of com-
plications of pregnancy. Details of this sub-study have
been previously published in a genetic association study
[15]. Briefly, this case-control study includes patients with
preterm prelabor rupture of membranes (pPROM) and
their neonates and control mothers with a normal preg-
nancy and their neonates. Patients of Hispanic origin
were enrolled in a research protocol at the Sotero del Rio
Hospital, Santiago, Chile.
pPROMoccurs in 3%–4.5% of pregnancies in the United
States and is responsible for about 30% of preterm
births [15]. Although previous studies have suggested
the presence of predisposing genetic factors for pPROM
[9,10,36,37], the underlying genetic architecture remains
unclear. SNPs in 190 candidate genes were selected and
genotyped based on their possible biological roles in
obstetrical diseases. We analyzed phenotypic and geno-
type data from the study to determine whether incompati-
bilities between the maternal and fetal genotypes increase
the risk of pPROM. Six samples were removed because of
large proportion of missing genotypes (> 50%) in either
the mother sample or the offspring sample. Also, when
searching across SNPmarkers, samples that did not follow
Mendelian inheritance were excluded from the analysis.
Our analysis included 742 SNPs in 190 candidate genes for
721 mother-offspring pairs (case-control ratio = 136:585).
Maternal age which has been previously shown to be sta-
tistically significant [15] was included in the model to
adjust its effect. The proposed 2-step procedure and the
full model approach were used to analyze data. Table 4
presents results of the analysis.The permutation proce-
dure was handled a bit differently in the model selection
step in this analysis: we calculated the maximum informa-
tion gain ratio at all genomic loci across the genome for
each permutation, that is, 742 values for 1 permutation;
and the maximum information gain ratios for 20 permu-
tations (a total of 742×20 = 14840 values) were collected
Table 4 List of SNPs withmaternal-fetal genotype incompatibility effect associatedwith pPROM at α = 0.005
Gene Region rs Number P-value1 P-value2 MS OR* 95% CI
MGP promoter rs1800801 0.0006 0.0404 5 0.4175 [0.2343, 0.7438]
MMP14 exon 5 rs2236302 0.0014 0.0051 3 2.8013 [1.6398, 4.7854]
COL5A2 exon 48 rs6434312 0.0017 0.0045 10 0.5370 [0.3502, 0.8233]
ANGPT2 intron 6 rs2979671 0.0020 0.1450 1 0.2820 [0.0968, 0.8216]
ANGPT2 exon 4 rs3020221 0.0020 0.0259 1 0.2826 [0.0947, 0.8434]
TNFRSF1A intron 4 rs1800692 0.0022 0.0968 7 2.1064 [1.3307, 3.3342]
AQP2 exon 4 629722653 0.0027 0.0271 2 2.8062 [1.4721, 5.3495]
CRHR1 intron 7 rs16940668 0.0038 0.0038 11 1.7365 [1.1605, 2.5986]
COL1A2 intron 46 rs13240759 0.0041 0.0041 9 0.5305 [0.3404, 0.8265]
GJA4 exon 2 rs1764389 0.0044 0.0044 11 1.6831 [1.1005, 2.5740]
HLA-E exon 3 rs1264457 0.0046 0.6216 8 0.5468 [0.3491, 0.8566]
IL10 intron 4 rs5743627 0.0048 0.0048 11 1.3354 [0.8149, 2.1885]
COL4A2 intron 33 rs41315048 0.0049 0.0101 10 0.5709 [0.3718, 0.8767]
1: P-value obtained using the 2-step approach;
2: P-value obtained using the full model approach;
*Odds ratio for the MFGI effect;
MS: Model selection result;
OR: Odds ratio;
CI: Confidence interval.
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Table 5 Type I error for testing the MFGI effect under simulation Scenarios I-III
Scenario I Scenario II Scenario III
HWE/D* Model n = 500 n = 1000 n = 500 n = 1000 n = 500 n = 1000
HWE Full model 0.0566 0.0512 0.0475 0.0540 0.0527 0.0490
Model selection 0.0566 0.0512 0.0475 0.0540 0.0527 0.0492
HWD Full model 0.0511 0.0470 0.0492 0.0529 0.0536 0.0477
Model selection 0.0511 0.0470 0.0492 0.0537 0.0536 0.0483
*: HWE: Hardy-Weinberg equilibrium; HWD: Hardy-Weinberg disequilibrium.
and used to obtain empirical P-values. This reduces the
computational time and allows us to address themultiplic-
ity issue. A cut-off value of τ = 0.05 was used in themodel
selection step because we try to find as many true pos-
itives as possible, although the chance that we make the
type I error may be slightly inflated whenmaternal and/or
fetal main effects co-exist with the MFGI effect.
Results
Simulation results
To assess the type I error rate, we simulated the phenotype
under the null hypothesis of no MFGI effect. Specifically,
data were generated under Scenarios I-III with sample
sizes of 500 and 1000. Empirical type I error rates were
estimated as the proportion of simulations with P-value
less than 0.05 across 11,000 replicates. Overall, the test
size was well controlled at the nominal level (0.05) for both
approaches under all scenarios we considered. The esti-
mates of type I error rate for the model selection approach
relies on the cutoff value τ used in the model selection
step. According to our simulations, the empirical type I
error rate exceeds the nominal level slightly under scenar-
ios II and III, where either maternal or fetal main effect
was simulated, when a loose cutoff value of τ = 0.05 was
Figure 1 Statistical power estimates of the proposedmodel selection approach (solid) and the full model approach (dashed) for
Scenarios IV-IX (as given in Table 3) assuming HWEwith sample sizes of 500 (left) and 1000 (right) using 1000 replicates.
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used, the obtained empirical type I error rate is around
0.06 (detailed data not shown here). As the cutoff value
gets more stringent, the obtained empirical type I error
rates approaches to the nominal level. Table 5 presents
results of type I error rate obtained with τ = 0.0001,
which are controlled at the nominal level. The subsequent
power estimates were also based on τ = 0.0001. As shown
in Table 5, the type I error rate for our model selection
approach are the same as that for the full model approach
under most scenarios. This is because the model selec-
tion step almost always chooses the full model (Model
11) when there is no incompatibility effect, leading to the
same analysis model for both approaches. There was no
significant effect of HWD on type I error. Estimates of the
type I error rate for scenarios under HWD are comparable
to those for scenarios under HWE.
Figures 1 and 2 display statistical power estimates for
the proposedmodel selection approach and the full model
approach for testing MFGI. The testing power for our
model selection approach was generally higher than that
for the full model approach under all the scenarios con-
sidered. This improvement was more striking for larger
sample sizes. For scenarios that assume HWE, when
the MFGI effect was simulated together with maternal
and/or fetal main effects (Scenarios IV-VI), our method
improved the power, particularly when the true incom-
patibility model was Model 5. For example, our model
selection approach had a power of 0.631 whereas the full
model approach only had a power of 0.126 to detect the
true MFGI effect when Model 5 was used to generate
data with a sample size 1000 under Scenario IV (top right
panel of Figure 1). When only the MGFI effect was sim-
ulated (Scenarios VII-IX), our model selection approach
increased the testing power, especially when the under-
lying true incompatibility model was Model 1, 2, or 5
(bottom panels of Figure 1). The increase in testing power
results from the model selection step, which can choose
the true data generating model. The estimated probabil-
ity of the underlying incompatibility model being selected
as the analysis model by our approach approaches 1 with
a heritability level of 0.1 or above. With a lower heri-
tability level of 0.05, the estimated probability of selecting
true model deceases, especially for scenarios under HWD
(right panel of Figure 3). Although improvements in the
Figure 2 Statistical power estimates of the proposedmodel selection approach (solid) and the full model approach (dashed) for
Scenarios IV-IX (as given in Table 3) not assuming HWEwith sample sizes of 500 (left) and 1000 (right) using 1000 replicates.
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Figure 3 Proportions of the simulations that select the true data generating model (black portion) for scenarios VII-IX (from top to
bottom) under HWE (left panel) and HWD (right panel) based on 1000 replicates.
testing power for HWD scenarios were not as striking as
those inHWE scenarios (Figure 2), the performance of our
2-step approach was still better than that of the full model
approach.
Data analysis results
Table 4 summarizes results of the pPROM data anal-
ysis for the 2 approaches. It is evident from the table
that our 2-step approach identified MFGIs that could be
missed by the full model approach. For example, a P-
value of 0.002 was obtained for both SNPs (rs2979671
and rs3020221) in the intron 6 and exon 4 regions of the
gene ANGPT2 by using our proposed approach. However,
the P-values of 0.1450 and 0.0259 were obtained for SNPs
rs2979671 and rs3020221, respectively, by using the full
model approach. Model 1 was selected as the incompat-
ibility model for SNP rs2979671 in ANGPT2. SNPs with
an odds ratio (OR) less than 1 showed protective effects
with the defined genotype incompatibility combinations
(Table 4). Here, OR refers to the ratio of odds of develop-
ing pPROM in the two risk groups defined by the selected
MFGI model. For example, SNP rs2979671 in ANGPT2
had an OR of 0.282, which implies that individuals with
the mother offspring paired genotype combination (A/A,
G/A) have a lower likelihood than other genotypes of
developing pPROM. Such protective effects were also
observed for SNPs identified in genes MGP, COL5A2,
COL1A2, HLA-E, and COL4A2 (ORs and CIs shown in
Table 4).
In comparison, SNPs identified in genes MMP14,
TNFRSF1A, AQP2, CRHR1, and GJA4 had OR greater
than 1, indicating that a high risk of pPROM is possible
with the mother-offspring pairs who have certain geno-
type incompatibility combinations defined by the corre-
sponding selected incompatibility models. For example,
SNP rs2236302 in the exon 5 region of gene MMP14,
mother-offspring pairs who have the genotype combina-
tion (C/G, C/C) are at higher risk of developing pPROM:
33 of the 104 mothers in the defined “high risk” group
developed pPROMwhereas only 99 of 611 mothers in the
“low-risk” group developed pPROM (OR = 2.8013, 95%
CI = [1.6398, 4.7854]). The confidence interval of the OR
for SNP rs5743627 in gene IL10 covers 1, indicating that
the MFGI effect is not marginally significant. As we are
aware of, this is the first analysis that have been done
which specifically investigates the genotype incompatibil-
ity effect between maternal and fetal gene that underlying
pPROM. We believe that our analysis results are helpful
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for generating hypotheses for future studies or wet lab
validations.
Discussion and conclusions
The importance of maternal-fetal genotype incompati-
bility in human diseases, particularly in obstetrical com-
plications, was first discussed in the 1990s [38] and has
been studied intensively in recent years [16-19,23,24,26].
Most of the currently available statistical methods for
identifying MFGI effects fall in the framework of general-
ized linear regression [20-22,25,30]. Since the underlying
MFGI mechanism is unknown and may vary for different
genetic variants, it is challenging to appropriately model
the incompatibility effect. The complexity largely relies
on the underlying competition of 3 sets of genes: the
maternally-derived fetal gene, the paternally-derived fetal
gene, and the untransmitted maternal gene [39]. Conflict
among the 3 sets of genes may result in an incompatibility
effect, which may adversely lead to pregnancy complica-
tions such as pPROM.
A commonly used approach is to code the incompat-
ibility effect whenever there is a disagreement between
maternal and fetal genotypes [30]. However, our simula-
tion studies show that this simple treatment ignores the
underlying disease gene action modes and has potential
drawbacks.Whenmaternal and/or fetal main effects exist,
the method increases the false-positive rates for incom-
patibility detection. Rather than predefining an incompat-
ibility model, herein, we propose a strategy to select an
optimal incompatibility model that captures the under-
lying disease gene function. A model is selected as a
candidate model if its entropy-based measurement is the
maximum among all possible incompatibility models via
a permutation procedure. The candidate model is then
chosen as the analytical model for further statistical tests
to assess the incompatibility effect along with the mater-
nal/fetal main genetic effects.
Intuitively, our approach will boost the statistical power
by adding a MFGI model selection step. The power gain
results from the fact that the true underlying incom-
patibility model can be selected most of the time with
enough samples. We conducted extensive simulation
studies, considering the effect of heritability, assump-
tion about HWE, sample size and different disease gene
functions. The results indicate that the proposed 2-step
strategy works well when the underlying truth is unknown
compared with the full model approach. Our approach
controls the type I error rate at the nominal level and
achieves higher power than the full model approach
without performing incompatibility model selection. Our
approach does not pose strong assumptions, and its per-
formance is quite consistent under settings such as HWE
or HWD, with or without maternal and/or fetal main
effects.
We applied the 2-step approach to study maternal-fetal
genotype incompatibility effects associated with pPROM
and identified several interesting SNPs. Our findings pro-
vide clues about the biological mechanism through which
MFGI in these genes may have an adverse or protective
effect on pPROM. Our results can be used to gener-
ate hypotheses for future biological validations to study
pathogenesis of pPROM.
Overall, this method can be applied to study the
maternal-fetal genotype incompatibility component of
obstetrical complications, such as preeclampsia and other
human diseases in which maternal and fetal genetic fac-
tors interact and increase the risk of disease.
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